Table 1.

Mutations

RNF43	somatic mutation in 18% (35/185) of colorectal adenocarcinomas and endometrial carcinomas 201 somatic mutation in 14% (8/57) of intraductal papillary mucinous neoplasms of the pancreas 202 Somatin mutation in 4.8% of MSS (microsatellite stable) and 54.6% of MSI (microsatellite instable) group of gastric cancers 203 mutation in 4% (1 out of 23) pancreatic carcinomas 204 mutated in 13.3% (2 out of 15) mucinous ovarian carcinoma 205; mutation in 9% (2/22) mucinous ovarian borderline tumors and 21% (6/29) mucinous ovarian carcinomas 206 mutation in 9.4% (5 out of 54) liver fluke–associated cholangiocarcinomas 207
CBL	mutation in 10% of myeloid neoplasms 208, 209 mutation in Juvenile myelomonocytic leukemia 210
BIRC2/BIRC3	BIRC2/BIRC3 mutation in multiple myeloma 211 BIRC3 mutation in the splenic marginal zone lymphoma (SMZL) 212 BIRC3 mutation in the mantle cell lymphoma (MCL) 213
PARK2	mutation in the familial lung cancers 187 mutation in glioblastoma, lung cancer 42
ZNRF3	deletion or mutation in adrenocortical carcinoma 214, 215
UBE3C	mutation in hepatocellular carcinoma 216
KEAP1	mutation in 12% lung squamous cell carcinoma 217, 218 mutation in clear-cell renal cell carcinoma 37 mutation in hepatocellular carcinoma 219 mutation in non-small cell lung carcinoma 220 mutation in 60% pulmonary papillary adenocarcinoma 221 mutation in 19% non-small cell lung carcinoma 222
UBR5	mutated in 18% mantle cell lymphoma 223